Vivitrol in Opiate Addiction Treatment

Vivitrol® is a new product of Alkermes (a U.S. based pharmaceutical company who specialize in disease management medications). Vivitrol received FDA approval in October 2010 for use in the prevention of opioid relapse following opioid detoxification. It is an extended release formulation of naltrexone designed to be administered through a once monthly IM (intramuscular) injection.

The medication is a non-addictive, opioid antagonist that blocks the effects of opioids, and thus discourages opioid misuse since no subjective euphoria is experienced. Opioid addicted individuals are often at high risk for relapse following opioid detox, and intensive support is very helpful in assisting these individuals with establishing a comfortable, lasting sobriety following successful opioid detox.

Vivitrol must be administered by a healthcare professional, and recipients should not have active liver disease complications since naltrexone (the active ingredient in Vivitrol) is contraindicated for those with acute hepatitis. Like any medication-assisted intervention, Vivitrol should be used in conjunction with ongoing behavioral health counseling in order to maximize a client's chance of successful long term recovery through skill development and lifestyle change.

The medication is not inexpensive (obviously a patented medication with no available generic equivalent). But considering its potential benefit to those in early recovery, it may be a worthwhile short-term investment in the first 30 to 90 days when recovering persons are at highest risk for opioid relapse. An obvious benefit of Vivitrol is that the patient does not have to take a daily pill, so either accidental or purposeful missed doses are not a concern.